0.65Open0.65Pre Close0 Volume413 Open Interest4.50Strike Price0.00Turnover109.93%IV7.67%PremiumDec 20, 2024Expiry Date0.33Intrinsic Value100Multiplier23DDays to Expiry0.32Extrinsic Value100Contract SizeAmericanOptions Type-0.5521Delta0.3457Gamma6.42Leverage Ratio-0.0097Theta-0.0016Rho-3.54Eff Leverage0.0041Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet